PENELOPE-B: Palbociclib Disappoints in HR+, HER2– Breast Cancer ...Middle East

News by : (Medscape) -
The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with HR+, HER2-negative primary breast cancer, according to first results from the PENELOPE-B trial. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( PENELOPE-B: Palbociclib Disappoints in HR+, HER2– Breast Cancer )

Also on site :

Most Viewed News
جديد الاخبار